Eosinophilic Pneumonia

Categories: Blood diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Eosinophilic Pneumonia

MalaCards integrated aliases for Eosinophilic Pneumonia:

Name: Eosinophilic Pneumonia 12 15 17 71
Pneumonia, Eosinophilic 12 74
Pulmonary Eosinophilia 43 71
Asthmatic Pulmonary Eosinophilia 71
Simple Pulmonary Eosinophilia 71
Pneumonia Eosinophilic 54


External Ids:

Disease Ontology 12 DOID:5870
MeSH 43 D011657
NCIt 49 C35150
ICD10 32 J82
UMLS 71 C0034068 C0242459 C0340076 more

Summaries for Eosinophilic Pneumonia

Disease Ontology : 12 A pneumonia in which certain type of white blood cell called an eosinophil accumulates in the lung. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. It is caused by certain medications or environmental triggers, parasitic infections, and cancer. The most common symptoms include cough, fever, difficulty breathing, and sweating at night.

MalaCards based summary : Eosinophilic Pneumonia, also known as pneumonia, eosinophilic, is related to chronic eosinophilic pneumonia and loeffler syndrome, and has symptoms including hemoptysis and coughing. An important gene associated with Eosinophilic Pneumonia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitric Oxide and Ciclesonide have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Eosinophilic pneumonia is a disease in which an eosinophil, a type of white blood cell, accumulates in... more...

Related Diseases for Eosinophilic Pneumonia

Diseases in the Eosinophilic Pneumonia family:

Chronic Eosinophilic Pneumonia

Diseases related to Eosinophilic Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic pneumonia 33.6 RNASE3 IL6 IL5 CD69 CCL5 CCL11
2 loeffler syndrome 32.2 IL5 IL33 IL13
3 cytokine deficiency 30.5 IL5 IL13
4 toxocariasis 30.5 RNASE3 IL5 IL4
5 filarial elephantiasis 30.4 IL5 IL4 IL13
6 sarcoidosis 1 30.3 SFTPD IL13 CD69 CCL5 CCL11
7 cryptogenic organizing pneumonia 30.3 SFTPD MUC1 CXCL8
8 interstitial pneumonitis, desquamative, familial 30.2 SFTPD MUC1
9 allergic bronchopulmonary aspergillosis 30.1 SFTPD IL5 IL4 CCL22 CCL17
10 ige responsiveness, atopic 30.1 RNASE3 IL5 IL4 IL13
11 hypereosinophilic syndrome, idiopathic 30.1 IL5 IL3
12 acute interstitial pneumonia 30.1 SFTPD MUC1
13 respiratory syncytial virus infectious disease 30.1 IL5 IL13 CCL5
14 paragonimiasis 30.0 RNASE3 IL5 IL13 CCL17
15 churg-strauss syndrome 30.0 RNASE3 IL5 IL3 CXCL8 CCL17 CCL11
16 bacterial pneumonia 29.9 SFTPD IL6 CXCL8
17 toxic oil syndrome 29.9 IL5 IL4
18 pulmonary fibrosis 29.9 SFTPD IL13 CXCL8 CCL22 CCL17
19 bronchiolitis obliterans 29.9 SFTPD IL6 IL13 CXCL8
20 nonspecific interstitial pneumonia 29.9 SFTPD MUC1 IL13 CCR4
21 elephantiasis 29.9 RNASE3 IL5 IL4 IL13
22 extrinsic allergic alveolitis 29.9 SFTPD IL6 CXCL8 CCL5
23 disseminated eosinophilic collagen disease 29.8 RNASE3 IL5 IL3 CCL17
24 wells syndrome 29.8 RNASE3 IL5 CXCL8
25 thrombocytosis 29.7 IL6 IL3 CSF2
26 folliculitis 29.7 IL5 IL4 CCL5 CCL11
27 exanthem 29.7 IL6 CXCL8 CSF2
28 filariasis 29.7 IL6 IL5 CCL5
29 cutaneous t cell lymphoma 29.6 IL5 IL4 CCR4 CCL17
30 adult respiratory distress syndrome 29.6 SFTPD IL6 CXCL8
31 idiopathic interstitial pneumonia 29.6 SFTPD IL4 IL13 CXCL8
32 ulcerative colitis 29.5 IL6 IL4 IL13 CXCL8
33 pharyngitis 29.5 IL6 CXCL8 CSF2
34 echinococcosis 29.5 RNASE3 IL6 IL5 CCL17
35 myelitis 29.5 IL6 CXCL8 CCL11
36 pneumocystosis 29.4 SFTPD MUC1 IL6
37 severe acute respiratory syndrome 29.3 IL6 CXCL8 CCL5
38 lymphoma, hodgkin, classic 29.2 IL3 IL13 CSF2 CCR4 CCL17
39 cellulitis 29.2 RNASE3 IL6 IL5 IL4
40 colitis 29.2 IL6 IL4 IL13 CXCL8
41 respiratory failure 29.2 SFTPD RNASE3 IL6 IL5 IL13 CXCL8
42 chickenpox 29.1 MUC1 IL6 IL4
43 ascaris lumbricoides infection 29.1 IL6 IL5 IL13 CXCL8
44 pneumoconiosis 29.0 IL6 IL4 CXCL8
45 toxic shock syndrome 28.9 IL6 IL4 CXCL8
46 osteomyelitis 28.9 IL6 IL4 IL13 CXCL8 CCL5
47 urticaria 28.8 RNASE3 IL6 IL5 IL4 IL13
48 neutropenia 28.8 IL6 IL3 CXCL8 CSF2
49 hypereosinophilic syndrome 28.8 RNASE3 IL5 IL4 IL3 IL13 CXCL8
50 arthritis 28.8 IL6 IL4 IL13 CXCL8 CSF2 CCL5

Graphical network of the top 20 diseases related to Eosinophilic Pneumonia:

Diseases related to Eosinophilic Pneumonia

Symptoms & Phenotypes for Eosinophilic Pneumonia

UMLS symptoms related to Eosinophilic Pneumonia:

hemoptysis, coughing

MGI Mouse Phenotypes related to Eosinophilic Pneumonia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 CCL11 CCL17 CCL5 CCR4 CD69 CSF2
2 immune system MP:0005387 9.77 CCL11 CCL17 CCL22 CCL5 CCR4 CD69
3 respiratory system MP:0005388 9.28 CCL11 CCR4 CSF2 IL13 IL33 IL4

Drugs & Therapeutics for Eosinophilic Pneumonia

Drugs for Eosinophilic Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Nitric Oxide Approved Phase 4 10102-43-9 145068
Ciclesonide Approved, Investigational Phase 4 141845-82-1, 126544-47-6 444033
Omalizumab Approved, Investigational Phase 4 242138-07-4
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10 Benralizumab Approved, Investigational Phase 4 1044511-01-4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Budesonide Approved Phase 4 51333-22-3 63006 5281004
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Gastrointestinal Agents Phase 4
17 Neuroprotective Agents Phase 4
18 Antiemetics Phase 4
19 Anti-Allergic Agents Phase 4
20 Antibodies Phase 4
21 Antibodies, Monoclonal Phase 4
22 Immunoglobulins Phase 4
23 Antiviral Agents Phase 4
24 Anti-Bacterial Agents Phase 4
25 Anti-Infective Agents Phase 4
26 Hormones Phase 4
27 Methylprednisolone Acetate Phase 4
28 glucocorticoids Phase 4
29 Antineoplastic Agents, Hormonal Phase 4
30 Hormone Antagonists Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Respiratory System Agents Phase 4
33 Anti-Asthmatic Agents Phase 4
34 Neurotransmitter Agents Phase 4
35 Adrenergic beta-Agonists Phase 4
36 Adrenergic Agents Phase 4
37 Albuterol Phase 4
38 Adrenergic Agonists Phase 4
39 Tocolytic Agents Phase 4
40 Bronchodilator Agents Phase 4
41 Formoterol Fumarate Phase 4
42 Budesonide, Formoterol Fumarate Drug Combination Phase 4
Reslizumab Approved, Investigational Phase 3 241473-69-8
44 Pharmaceutical Solutions Phase 3
45 Immunoglobulins, Intravenous Phase 3
46 Immunoglobulin G Phase 3
47 Protective Agents Phase 3
48 Antioxidants Phase 3
49 silymarin Phase 3
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2 Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
3 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial Recruiting NCT04319705 Phase 4 Azithromycin;Placebo oral tablet
5 A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Recruiting NCT04228588 Phase 4 Mepolizumab 100 MG [Nucala]
6 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
7 SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Not yet recruiting NCT04159519 Phase 4 Symbicort®;Fasenra®;Ventolin®
8 A Phase 4, Open-label, Single Arm, 24-week, Phase 4 Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged >=18 Years With Severe Eosinophilic Asthma Requiring Oral Corticosteroid Treatment to Maintain Asthma Control (PRISM) Not yet recruiting NCT04276233 Phase 4 Prednisone/ Prednisolone;Salbutamol
9 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
10 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
11 A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
12 A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
13 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
14 A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) Completed NCT02555371 Phase 3 Placebo
15 Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
16 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
17 A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma Recruiting NCT04049175 Phase 3 Treatment A;Treatment B;Treatment C;Treatment D
18 An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children With Severe Eosinophilic Asthma Active, not recruiting NCT04305405 Phase 3 Benralizumab
19 Trial of Silymarin in Adults With COVID-19 Pneumonia Not yet recruiting NCT04394208 Phase 3 Silymarin;Placebo
20 An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
21 An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
22 A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
23 Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
24 The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial Completed NCT02560610 Phase 2 OC000459;Placebo
25 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
26 A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma Recruiting NCT04046939 Phase 2 low-dose dexpramipexole;mid-dose dexpramipexole;high-dose dexpramipexole;placebo oral tablet
28 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia Unknown status NCT01152424
29 Serum Cytokine Profiles of Severe Asthma Completed NCT03563521
30 Observational Retrospective Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain Completed NCT04126499
31 Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center Completed NCT03209934
32 Characteristics of the Eosinophilic Asthma Phenotype: an Observational Study in Patients From a Tertiary Care Center With Various Asthma Severities: The Quebec Heart and Lung Institute-Laval University Retrospective Asthma Database Analysis Completed NCT03696914
33 Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative Completed NCT03453021 Mepolizumab
34 Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin Recruiting NCT04414137
35 imPROve-asthma - A Prospective, 12-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany Recruiting NCT04184284
36 A Multicentre Single Arm Observational Prospective Study to Assess Demographic Characteristics Burden of Disease PRO's in Uncontrolled, Severe Eosinophilic Asthma Patients Aged 18y or Older and Qualifying for Treatment With Benralizumab in BE Recruiting NCT04221802
37 Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
38 A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma Recruiting NCT03739320 Mepolizumab 100 MG Injection [Nucala]
39 Effects of Anti-IL5 Biological Treatments of Total Blood IgE Levels in Severe Asthmatic Patients: Real-life Retrospective Multicenter Observational Study Recruiting NCT04181190
40 A Multicentre, Single Arm, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Eosinophilic Asthma Patients Older Than 18 Starting Benralizumab in Switzerland Recruiting NCT03907137
41 Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease Recruiting NCT02852928
42 Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients Recruiting NCT03976310 48 weeks of Benralizumab
43 Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece Active, not recruiting NCT04084613
44 A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Active, not recruiting NCT03733535 Benralizumab;129 Xenon
45 Peripheral Eosinophils Phenotypes in Airway Inflammatory Diseases: Towards Proper Clustering and Therapeutic Targeting Not yet recruiting NCT04187976

Search NIH Clinical Center for Eosinophilic Pneumonia

Cochrane evidence based reviews: pulmonary eosinophilia

Genetic Tests for Eosinophilic Pneumonia

Anatomical Context for Eosinophilic Pneumonia

MalaCards organs/tissues related to Eosinophilic Pneumonia:

Lung, T Cells, Testes, Bone, Bone Marrow, Breast, Heart

Publications for Eosinophilic Pneumonia

Articles related to Eosinophilic Pneumonia:

(show top 50) (show all 1926)
# Title Authors PMID Year
[Total serum IgE levels in eosinophilic lung diseases]. 61 54
16883101 2006
Elevation of macrophage-derived chemokine in eosinophilic pneumonia: a role of alveolar macrophages. 54 61
15751278 2005
Accumulation of CCR4-expressing CD4+ T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. 54 61
12757454 2003
Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. 61 54
11956056 2002
Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease. 54 61
11153599 2000
Elevated chemokine levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. 61 54
11031344 2000
Overexpression of CD44 on alveolar eosinophils with high concentrations of soluble CD44 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. 61 54
10688432 1999
[Evaluation of eosinophilic cationic protein levels in patients with eosinophilic pneumonia]. 54 61
9893428 1998
Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. 61 54
7921434 1994
[Expression of activation antigen, CD69, on human local eosinophils]. 61 54
8031251 1994
[Characterization of a receptor for interleukin-5 on pulmonary eosinophils with eosinophilic pneumonia]. 61 54
1306241 1992
[Ultrastructural observation of eosinophils in bronchoalveolar lavage fluid in eosinophilic pneumonia]. 54 61
1484434 1992
In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. 61 54
1500624 1992
Lung fibroblasts produce interleukin-33 in response to stimulation by retinoblastoma-binding protein 9 via production of prostaglandin E2. 61
32484881 2020
[Daptomycin-induced eosinophilic pneumonia associated with an early endoprosthesis infection]. 61
32270225 2020
Tegafur/gimeracil/oteracil-induced eosinophilic pneumonia. 61
32180985 2020
Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia. 61
32009090 2020
Smoking-associated interstitial lung disease: update and review. 61
32379511 2020
Severe clopidogrel-induced DRESS with eosinophilic pneumonia associated with Epstein-Barr virus reactivation. 61
32110414 2020
Possible Mechanisms of Eosinophil Accumulation in Eosinophilic Pneumonia. 61
32326200 2020
Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. 61
32052155 2020
Eosinophilic Pneumonia and Lymphadenopathy Associated With Vaping and Tetrahydrocannabinol Use. 61
32217740 2020
[Acute Eosinophilic Pneumonia (AEP) after Hookah Smoking]. 61
32274781 2020
Acute lung injury secondary to e-cigarettes or vaping. 61
32313466 2020
Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series. 61
32282447 2020
Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia. 61
31778113 2020
Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty. 61
31890213 2020
Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions. 61
31990264 2020
Exon 8 KIT mutation and pulmonary eosinophilia. 61
32168380 2020
Daptomycin associated eosinophilic pneumonia. 61
32098706 2020
Vaping-Associated Acute Respiratory Failure Due to Acute Lipoid Pneumonia. 61
31583455 2020
Unilateral antibiotic-induced acute eosinophilic pneumonia on the operative side after surgery for primary lung cancer: a case report. 61
32076875 2020
Vaping-associated acute respiratory distress syndrome. 61
31820270 2020
Filarial tropical pulmonary eosinophilia. 61
30720371 2020
Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia. 61
30444149 2020
[Acute eosinophilic pneumonia and illicit psychoactive substance use]. 61
31862136 2020
Chemotherapy-induced pulmonary complications in cancer: Significance of clinicoradiological correlation. 61
32476746 2020
[Pulmonary complications in cocaine users]. 61
31883817 2020
32435015 2020
Acute Eosinophilic Pneumonia Secondary to Menthol Cigarette Use: A Rare Phenomenon With a Review of Literature. 61
32462944 2020
Acute Eosinophilic Pneumonia: A Rare Complication of Daptomycin Therapy. 61
32140361 2020
Vaping-induced diffuse alveolar hemorrhage. 61
31956478 2020
Chronic Eosinophilic Pneumonia Masquerading As Bronchogenic Malignancy. 61
32021850 2020
Vaping Is Not Safe: A Case of Acute Eosinophilic Pneumonia following Cannabis Vapor Inhalation. 61
32047695 2020
Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia. 61
32373456 2020
Acute eosinophilic pneumonia associated with non-cigarette smoking products: a systematic review. 61
32383466 2020
First report of Aelurostrongylus abstrusus in St. Kitts. 61
32057393 2020
Association between peripheral blood/bronchoalveolar lavage eosinophilia and significant oxygen requirements in patients with acute eosinophilic pneumonia. 61
31992279 2020
Discordant bilateral bronchoalveolar lavage findings in a patient with acute eosinophilic pneumonia associated with counterfeit tetrahydrocannabinol oil vaping. 61
32071854 2020
Acute eosinophilic pneumonia with sepsis-like symptoms of arthralgia, joint stiffness and lymph node enlargement: A case report. 61
32477860 2020

Variations for Eosinophilic Pneumonia

Expression for Eosinophilic Pneumonia

Search GEO for disease gene expression data for Eosinophilic Pneumonia.

Pathways for Eosinophilic Pneumonia

Pathways related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
Show member pathways
14.01 RNASE3 MUC1 IL6 IL5 IL4 IL33
Show member pathways
13.83 MUC1 IL6 IL5 IL4 IL3 IL13
Show member pathways
13.68 IL6 IL5 IL4 IL33 IL3 IL13
Show member pathways
13.55 IL6 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
13.4 IL6 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
13.34 MUC1 IL6 IL5 IL4 IL33 IL3
Show member pathways
13.21 IL6 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
12.92 RNASE3 IL6 IL5 IL4 IL3 IL13
Show member pathways
12.89 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
Show member pathways
12.87 IL6 CXCL8 CSF2 CCR4 CCL5
11 12.85 IL6 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
12.59 IL5 IL4 IL3 IL13 CSF2
Show member pathways
12.5 IL6 IL5 IL4 IL3 IL13 CSF2
Show member pathways
12.41 IL6 CXCL8 CCR4 CCL5 CCL22 CCL17
Show member pathways
12.34 IL6 IL5 IL4 IL13 CXCL8 CSF2
Show member pathways
12.31 IL6 IL5 IL4 IL3 IL13 CXCL8
Show member pathways
18 12.25 IL6 IL3 CXCL8 CSF2
19 12.1 IL6 IL5 IL4 IL3 CSF2 CD69
20 12.03 MUC1 IL6 IL4 IL13 CXCL8 CCL22
21 11.99 IL6 IL5 IL4 IL3 CSF2
22 11.91 IL6 CSF2 CCL5
23 11.91 IL6 CXCL8 CSF2 CCL5
24 11.89 IL6 IL5 IL4 IL13 CXCL8 CSF2
25 11.88 IL6 IL3 CXCL8
Show member pathways
11.87 IL5 IL4 IL3 CXCL8 CSF2
27 11.86 IL6 CXCL8 CSF2
28 11.84 IL5 IL4 IL33 IL13
Show member pathways
11.82 IL6 CXCL8 CSF2
30 11.73 IL5 IL4 CCL17 CCL11
Show member pathways
11.64 IL6 CXCL8 CSF2
32 11.59 IL6 IL5 IL3 CSF2
33 11.51 IL6 CXCL8 CCL11
34 11.41 IL6 IL5 IL4 IL33 IL13
35 11.39 IL6 IL4 IL13 CXCL8 CSF2 CCL5
36 11.26 IL6 IL5 IL4 IL3 IL13 CSF2
37 11.24 IL5 IL4 IL13
38 11.16 IL5 IL4 IL33 IL13 CCL22 CCL17
39 11.02 IL6 IL5 IL4 IL13 CXCL8 CSF2
40 10.95 IL6 IL5 IL4 IL13
41 10.9 IL6 IL5 IL4 IL3 IL13 CXCL8

GO Terms for Eosinophilic Pneumonia

Cellular components related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 SFTPD RNASE3 MUC1 IL6 IL5 IL4
2 extracellular space GO:0005615 9.5 SFTPD RNASE3 MUC1 IL6 IL5 IL4

Biological processes related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.22 IL6 IL5 IL4 CXCL8 CCR4 CCL5
2 positive regulation of cell proliferation GO:0008284 10.03 IL6 IL5 IL4 IL3 CSF2
3 positive regulation of gene expression GO:0010628 10 IL6 IL4 IL33 IL13 CSF2
4 positive regulation of GTPase activity GO:0043547 9.98 CCL5 CCL22 CCL17 CCL11
5 MAPK cascade GO:0000165 9.94 IL5 IL3 CSF2 CCL5
6 cell-cell signaling GO:0007267 9.92 IL3 CCL5 CCL22 CCL17
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.9 CCL5 CCL22 CCL17 CCL11
8 cellular response to tumor necrosis factor GO:0071356 9.89 CXCL8 CCL5 CCL22 CCL17 CCL11
9 chemotaxis GO:0006935 9.88 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
10 response to virus GO:0009615 9.85 CCL5 CCL22 CCL11
11 cellular response to interleukin-1 GO:0071347 9.85 CXCL8 CCL5 CCL22 CCL17 CCL11
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 IL6 IL5 IL3
13 cellular response to interferon-gamma GO:0071346 9.84 CCL5 CCL22 CCL17 CCL11
14 neutrophil chemotaxis GO:0030593 9.83 CXCL8 CCL5 CCL22 CCL17 CCL11
15 cell chemotaxis GO:0060326 9.82 CCR4 CCL5 CCL22
16 inflammatory response GO:0006954 9.81 IL6 IL5 IL13 CXCL8 CCR4 CCL5
17 chemokine-mediated signaling pathway GO:0070098 9.8 CXCL8 CCR4 CCL5 CCL22 CCL17 CCL11
18 lymphocyte chemotaxis GO:0048247 9.78 CCL5 CCL22 CCL17 CCL11
19 monocyte chemotaxis GO:0002548 9.77 IL6 CCL5 CCL22 CCL17 CCL11
20 positive regulation of T cell proliferation GO:0042102 9.76 IL6 IL4 CCL5
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 IL6 IL13 CCL5
22 positive regulation of B cell proliferation GO:0030890 9.74 IL5 IL4 IL13
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IL6 IL4 IL3 IL13 CSF2 CCL5
24 positive regulation of JAK-STAT cascade GO:0046427 9.72 IL6 IL5 CCL5
25 macrophage activation GO:0042116 9.7 IL4 IL13 CSF2
26 cytokine-mediated signaling pathway GO:0019221 9.7 MUC1 IL6 IL5 IL4 IL3 IL13
27 positive regulation of immunoglobulin secretion GO:0051024 9.69 IL6 IL5 IL33
28 dendritic cell differentiation GO:0097028 9.67 IL4 CSF2
29 macrophage chemotaxis GO:0048246 9.67 SFTPD CCL5
30 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.67 CXCL8 CCL5
31 positive regulation of neuroinflammatory response GO:0150078 9.66 IL6 IL33
32 positive regulation of podosome assembly GO:0071803 9.65 IL5 CSF2
33 neutrophil activation GO:0042119 9.65 CXCL8 CCL5
34 positive regulation of interleukin-10 secretion GO:2001181 9.64 IL4 IL13
35 positive regulation of mast cell degranulation GO:0043306 9.63 IL4 IL13
36 positive regulation of interleukin-13 production GO:0032736 9.61 IL4 IL33
37 induction of bacterial agglutination GO:0043152 9.59 SFTPD RNASE3
38 negative regulation of complement-dependent cytotoxicity GO:1903660 9.56 IL4 IL13
39 immune response GO:0006955 9.4 IL6 IL5 IL4 IL3 IL13 CXCL8

Molecular functions related to Eosinophilic Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.65 IL6 IL5 IL4 IL3 CSF2
2 CCR chemokine receptor binding GO:0048020 9.46 CCL5 CCL22 CCL17 CCL11
3 cytokine activity GO:0005125 9.4 IL6 IL5 IL4 IL33 IL3 IL13
4 chemokine activity GO:0008009 9.35 CXCL8 CCL5 CCL22 CCL17 CCL11
5 CCR4 chemokine receptor binding GO:0031729 9.32 CCL5 CCL17

Sources for Eosinophilic Pneumonia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....